-
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
29 Apr 2025 11:54 GMT
… analysis. Additionally, rAAV gene therapy in these animals remained … further its pipeline of gene therapies in order to … lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is … Each of Genprex’s lung cancer clinical programs has received …
-
Lung Cancer Therapeutics Global Market Overview 2024: Asia Pacific Lung Cancer Market Grows Amid Government Healthcare Investments and Rising Patient Awareness as North America Leads - ResearchAndMarkets.com
22 Apr 2025 16:25 GMT
… and awareness of advanced gene therapies have driven the … Lung Cancer Therapeutic Cancer Types
Non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)
Lung Cancer … cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)
Global Lung Cancer Therapeutics …
-
Cancer Gene Therapy Market Expected to Achieve a Strong 13.37% CAGR, to Reach USD 32.0 Billion by 2035
22 Apr 2025 05:13 GMT
Breast and Lung Cancer dominate, driven by high incidence … care.
Target Disease
Breast and Lung Cancer dominate, driven by high incidence … pathways for advanced gene therapies.
Outlook and Opportunities
The Cancer Gene Therapy Market is …
-
Genprex Collaborators To Present Positive Preclinical Data On The Use Of Reqorsa® Gene Therapy For The Treatment Of Lung Cancer At The 2025 AACR Annual Meeting
26 Mar 2025 14:35 GMT
… for Ras inhibitor resistant lung cancer," said Ryan … researchers demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes … its pipeline of gene therapies in order to … product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is …
-
Opportunities and Obstacles for Personalized Cancer Vaccines
08 May 2025 12:24 GMT
… melanoma and non–small-cell lung cancer (NSCLC), the treatment is being … -affairs strategies for cell and gene therapies (CGTs), advanced therapies, nucleic-acid …
-
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
10 Mar 2025 12:00 GMT
… platform has successfully delivered transient gene therapy payloads to targeted tumors. … -stage metastatic cancers, including lung cancer, when intratumoral administration is … viral vector, delivering specific gene therapies directly to tumor sites. …
-
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System Is A Potential Treatment For Anti-PD1 Resistant Non-Small Cell Lung Cancer
13 Feb 2025 15:12 GMT
… metastatic non-small cell lung cancer (NSCLC) in a … a wide variety of lung cancers could potentially be targeted … KRAS mutations.
About Reqorsa® Gene Therapy
REQORSA (quaratusugene ozeplasmid) consists … further its pipeline of gene therapies in order to …
-
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2025 Earnings Call Transcript
07 May 2025 12:39 GMT
… therapeutic potential of biologics and gene therapies for the treatment of corneal … patients in non-small cell lung cancer, including an ORR of 27% …
-
Genprex doses first subject in expansion part of lung cancer gene therapy trial
24 Jan 2025 20:59 GMT
… the Reqorsa gene therapy (quaratusugene ozeplasmid) for extensive-stage small-cell lung cancer (ES … -SCLC) patients.
The trial will assess the gene therapy as … the Acclaim-3 subjects. The gene therapy has also been granted orphan …
-
Genprex starts patient dosing in phase 2 expansion portion of Acclaim─3 study of Reqorsa Gene Therapy in combo with Tecentriq to treat SCLC
24 Jan 2025 13:17 GMT
… Inc., a clinical-stage gene therapy company focused on developing … clinical study of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in … extensive stage small cell lung cancer (ES-SCLC).
“We … drug candidate, Reqorsa Gene Therapy, in combination with Genentech …
About
© 1995-2025